These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 22745564

  • 1. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.
    De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J.
    Clinicoecon Outcomes Res; 2012; 4():157-68. PubMed ID: 22745564
    [Abstract] [Full Text] [Related]

  • 2. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M, Álvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J.
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [Abstract] [Full Text] [Related]

  • 3. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
    Carrasco JL, Álvarez E, Olivares JM, Rejas J.
    Actas Esp Psiquiatr; 2013 Jun; 41(3):164-74. PubMed ID: 23803800
    [Abstract] [Full Text] [Related]

  • 4. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
    Álvarez E, Olivares JM, Carrasco JL, López-Gómez V, Rejas J.
    Ann Gen Psychiatry; 2015 Jun; 14(1):2. PubMed ID: 25632294
    [Abstract] [Full Text] [Related]

  • 5. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
    de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.
    Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
    [Abstract] [Full Text] [Related]

  • 6. Pregabalin versus sertraline in generalized anxiety disorder. An open label study.
    Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS, Boskovic K, Jovicevic M.
    Eur Rev Med Pharmacol Sci; 2015 May; 19(11):2120-4. PubMed ID: 26125277
    [Abstract] [Full Text] [Related]

  • 7. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, González-Gómez FJ, Ruiz L, Rejas J.
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
    Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G.
    Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
    [Abstract] [Full Text] [Related]

  • 9. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice.
    Ruiz MA, Álvarez E, Carrasco JL, Olivares JM, Pérez M, Rejas J.
    Drug Des Devel Ther; 2015 Feb; 9():4329-40. PubMed ID: 26273194
    [Abstract] [Full Text] [Related]

  • 10. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
    Darbà J, Kaskens L, Pérez C, Álvarez E, Navarro-Artieda R, Sicras-Mainar A.
    Adv Ther; 2014 Jan; 31(1):1-29. PubMed ID: 24390901
    [Abstract] [Full Text] [Related]

  • 11. Pregabalin: a review of its use in adults with generalized anxiety disorder.
    Frampton JE.
    CNS Drugs; 2014 Sep; 28(9):835-54. PubMed ID: 25149863
    [Abstract] [Full Text] [Related]

  • 12. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study.
    Benítez CI, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB.
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):5-13. PubMed ID: 18165458
    [Abstract] [Full Text] [Related]

  • 13. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms.
    Olivares JM, Álvarez E, Carrasco JL, Pérez Páramo M, López-Gómez V.
    Int Clin Psychopharmacol; 2015 Sep; 30(5):265-71. PubMed ID: 26111356
    [Abstract] [Full Text] [Related]

  • 14. Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT.
    Palmer R, Dimairo M, Latimer N, Cross E, Brady M, Enderby P, Bowen A, Julious S, Harrison M, Alshreef A, Bradley E, Bhadhuri A, Chater T, Hughes H, Witts H, Herbert E, Cooper C.
    Health Technol Assess; 2020 Apr; 24(19):1-176. PubMed ID: 32369007
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L.
    J Med Econ; 2013 Apr; 16(5):596-605. PubMed ID: 23409950
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan.
    Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, Willke R, Fujii K, Doherty J, Kobayashi M.
    Clinicoecon Outcomes Res; 2015 Apr; 7():505-20. PubMed ID: 26504403
    [Abstract] [Full Text] [Related]

  • 17. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder.
    Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S.
    World J Biol Psychiatry; 2012 Oct; 13(7):510-6. PubMed ID: 22059936
    [Abstract] [Full Text] [Related]

  • 18. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia.
    Mencacci C, Aguglia E, Biggio G, Cappellari L, Di Sciascio G, Fagiolini A, Maina G, Tortorella A, Katz P, Ripellino C.
    Clinicoecon Outcomes Res; 2013 Oct; 5():611-21. PubMed ID: 24348057
    [Abstract] [Full Text] [Related]

  • 19. A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan.
    Akazawa M, Igarashi A, Ebata N, Murata T, Zeniya S, Haga Y, Nozawa K, Fujii K, Taguchi T.
    J Pain Res; 2019 Oct; 12():2785-2797. PubMed ID: 31576163
    [Abstract] [Full Text] [Related]

  • 20. Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.
    Pérez C, Navarro A, Saldaña MT, Masramón X, Pérez M, Rejas J.
    Pain Med; 2013 Dec; 14(12):1954-63. PubMed ID: 24330229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.